Algeta ASA : schedules Second Quarter 2008 Presentation and Conference Call

Oslo, Norway, 11 August 2008 - Algeta ASA (OSE: ALGETA), the
Norwegian cancer therapeutics company, will announce its second
quarter 2008 results on Wednesday, 13 August 2008. A presentation to
investors, analysts and the press will take place in Oslo at 08:15
CET and an international conference call will take place at 14:30 CET
(details below). Algeta's President and Chief Executive Officer, Dr.
Thomas Ramdahl and Chief Financial Officer, Øystein Soug will host
the presentation and the call will be hosted by Thomas Ramdahl.


The presentation will take place at 08:15 CET at:

Hotel Continental
Stortingsgaten 24/26
0117 Oslo
Norway.

Breakfast will be served from 07:45 CET.

To participate in the conference call, please dial the appropriate
number below five minutes prior to the call:

800 80 119 (in Norway)
+47 23 00 04 00 (from abroad).

The results report and the presentation will be made available on
www.algeta.com in the Investors section from 08:00 CET.

A replay version of the call will be available until presentation of
third quarter 2008 12 November 2008. To access the replay, please
dial +47 67 89 40 91. Enter account no. 1428 followed by #, then
press 1, conference no. 428 followed by #. Press 1 to play. A replay
version of the conference call will also be available during the same
period at www.algeta.com.

###

For further information, please contact


Dr Thomas Ramdahl, CEO
Øystein Soug, CFO +47 23 00 79 90 / +47 913 91 458 (mob)
+47 23 00 79 84 / +47 906 56 525 (mob)
post@algeta.com

Dr Mark Swallow / David Dible +44 (0) 207 638 9571
Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk



About Algeta

Algeta ASA is a Norwegian cancer therapeutics company built on
world-leading, proprietary technology.

Algeta is developing new, targeted cancer therapeutics that harness
the unique characteristics of alpha particle emitters and are potent,
well-tolerated and convenient to use.

Algeta's lead product candidate, Alpharadin, is expected to enter
Phase III clinical trials in hormone refractory prostate cancer based
on positive Phase II results. Alpharadin is a novel bone-seeking
therapeutic based on the alpha particle emitter radium-223 and may
target skeletal metastases from multiple cancer types, as well as
primary bone cancers.

Algeta is also developing other technologies for delivering alpha
emitters. These include microparticles, liposomes, and methods to
enhance the potency of therapeutic antibodies and other
tumor-targeting molecules by linking them to the alpha particle
emitter thorium-227.

The Company is headquartered in Oslo, Norway, and was founded in
1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker:
ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.


Forward-looking Statement

This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on results of operations and the
financial condition of Algeta. There are a number of factors that
could cause actual results and developments to differ materially from
those expressed or implied by these forward-looking statements.
Theses factors include, among other things, risks associated with
technological development, the risk that research & development will
not yield new products that achieve commercial success, the impact of
competition, the ability to close viable and profitable business
deals, the risk of non-approval of patents not yet granted and
difficulties of obtaining relevant governmental approvals for new
products.

###


http://hugin.info/134655/R/1242248/267028.pdf


Copyright © Hugin AS 2008. All rights reserved.

Partner Area